Hosted on MSN23h
BTIG Downgrades Inari Medical (NARI)
Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
Hosted on MSN23h
BTIG Downgrades Palo Alto Networks (PANW)
Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...